Retreatment of intracranial gliomas

Howard J. Landy, Lynn Feun, James G. Schwade, Susan Snodgrass, Ying Lu, Fred Gutman

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Although intracranial gliomas carry a poor long-term prognosis, retreatment at the time of tumor progression may prolong survival and maintain or improve the quality of life. Thirty-three patients who underwent retreatment with surgery, radiotherapy, and chemotherapy were reviewed retrospectively. Median survival after initiation of retreatment was 8 months for glioblastoma, 13 months for anaplastic astrocytoma, 22 months for astrocytoma, and 47 months for oligodendroglioma/mixed glioma. Survival was significantly better for younger patients and for those with better functional status. One third of patients were neurologically improved by surgery. Surgical morbidity was minimal (2.1%); there was no surgical mortality. Chemotherapy and radiotherapy produced expected adverse reactions. Retreatment of intracranial gliomas carries acceptable risk and is beneficial in selected patients. Decisions regarding retreatment must be carefully individualized with consideration of the quality of life and the wishes of the patient and family.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalSouthern medical journal
Issue number2
StatePublished - Feb 1994

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Retreatment of intracranial gliomas'. Together they form a unique fingerprint.

Cite this